Institution Directory

Clinical trials at Memorial Sloan Kettering Cancer Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1680

Shown on this page

Current sort

Stored official records

Conditions: Breast Adenocarcinoma
Interventions: Bevacizumab, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Quality-of-Life Assessment; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 4,994 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 840
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 548 more

Conditions: Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIB Breast Cancer AJCC v7
Interventions: Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen Citrate; Drug · Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 10,273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2030
U.S. locations: 1160
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 723 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Durvalumab, Pumitamig; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 38
States / cities: Daphne, Alabama • Golden, Colorado • Newark, Delaware + 32 more

Conditions: Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Interventions: Pirtobrutinib, Rituximab, Venetoclax; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Interventions: Capox, Folfox, Nivolumab, Pumitamig; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 690 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 34
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 29 more

Conditions: Breast Cancer
Interventions: American Cancer Society booklet, Single Counseling Session; Other · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: T-cell NHL (PTCL or CTCL)
Interventions: KK2223; Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 14
States / cities: Duarte, California • Orange, California • Stanford, California + 11 more

Conditions: Lymphoma
Interventions: Calcium folinate, Cyclophosphamide, Fludarabine, Liso-cel, Methotrexate, Procarbazine, Rituximab, Temozolomide; Drug · Biological
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 14
States / cities: Aurora, Colorado • Tampa, Florida • Chicago, Illinois + 11 more

Conditions: Radical Prostatectomy, Stress Urinary Incontinence (SUI)
Interventions: Voro Urologic Scaffold; Device
Lead sponsor: Levee Medical, Inc.; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 15 more

Conditions: Anaplastic Lymphoma Kinase-positive, Non-small Cell Lung Cancer
Interventions: Alectinib, Neladalkib (NVL-655); Drug
Lead sponsor: Nuvalent Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 23
States / cities: Glendale, Arizona • Newport Beach, California • Orange, California + 19 more

Conditions: Breast Cancer
Interventions: PF-07220060, vepdegestrant; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 34
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 22 more

Conditions: Advanced Solid Tumor, Mesothelioma, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Squamous Lung Cancer, Non-small Cell Lung Adenocarcinoma, Renal Cancer
Interventions: NXP900; Drug
Lead sponsor: Nuvectis Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • La Jolla, California • Denver, Colorado + 9 more

About this Memorial Sloan Kettering Cancer Center institution page

What this page lists: ClinicalTrials.gov records that list Memorial Sloan Kettering Cancer Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Memorial Sloan Kettering Cancer Center

Filter and sort this campus

Stored official records

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

A Study of a One-Time Counseling Session to Help Reduce Depression, Anxiety, and Distress in People With Cancer

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Pivotal Study of Voro Urologic Scaffold

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

About this Memorial Sloan Kettering Cancer Center institution page